Health & Fitness
Health and FitnessHealth and Fitness 
Thu, May 24, 2012
A Forward Look, the Year Ahead - Featured Research on Jazz Pharmaceuticals and Human Genome Sciences
May 24, 2012 09:00 ET
A Forward Look, the Year Ahead - Featured Research on Jazz Pharmaceuticals and Human Genome Sciences
HONG KONG--(Marketwire - May 24, 2012) - Today, [ www.BollingerReport.com ] introduced featured coverage of Jazz Pharmaceuticals (
Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.
Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.
Bollinger Report screened and selected Jazz Pharmaceuticals for its current position within the healthcare industry. A copy of this report featuring Jazz Pharmaceuticals (
Bollinger Report is featuring Human Genome Sciences for its changing role within the healthcare industry. Human Genome Sciences, Inc. (HGS) is a biopharmaceutical company. The Company's products include BENLYSTA (belimumab) for systemic lupus erythematosus (SLE) and raxibacumab for inhalation anthrax. HGS continues to deliver raxibacumab to the United States Strategic National Stockpile (SNS) for emergency use in treating inhalation anthrax. To download researches and analysis on Human Genome Sciences (
About Bollinger Report
Bollinger Report has come to be known among its peers as a trusted source of information for both investors and technical traders. Our online content is continually updated, bringing fresh new researches and analyses to the investment community. John Bollinger and BollingerBands.com are not affiliated with BollingerReport.com and do not endorse the service or any of the recommendations made by the service.